Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study

Pediatric Pulmonology

Volumn 32, Issue 2, 2001, Pages 122-128

  Noone, Peadar G ^a   Hamblett, Nicole ^b   Accurso, Frank ^c   Aitken, Moira L ^d   Boyle, Michael ^e   Dovey, Mark ^f   Gibson, Ron ^d   Johnson, Craig ^e   Kellerman, Don ^f   Konstan, Michael W ^d   Milgram, Laura ^b   Mundahl, Jean ^g   Retsch Bogort, George ^h   Rodman, David ⁱ   Williams Warren, Judy ^b   Wilmott, Robert W ^j   Zeitlin, Pam ^e   Ramsey, Bonnie ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b CF Therapeutics Development Network   (United States)

^c CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^j Dayton Children's Hospital   (United States)

more..

Author keywords

Cystic fibrosis; INS 365; New therapies; P2Y2 receptors; Triphosphate nucleotides; Uridine 5 triphosphate

Indexed keywords

DIQUAFOSOL; NUCLEOSIDE TRIPHOSPHATE; PURINE P2Y RECEPTOR; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ADULT; AEROSOL; ARTICLE; CHILD; CHLORIDE TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; ION TRANSPORT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOCILIARY TRANSPORT; NEBULIZER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM EXAMINATION; TREATMENT OUTCOME;

ADOLESCENT; AEROSOLS; CHILD; COUGH; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; OPHTHALMIC SOLUTIONS; POLYPHOSPHATES; RESPIRATORY SOUNDS; SPUTUM; URACIL NUCLEOTIDES;

EID: 0034896551     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1098     Document Type: Article

References (23)

1. Cystic fibrosis - State of the art
2. Cystic fibrosis
3. Cystic fibrosis gene and functions of CFTR
4. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
5. Coordinated clearance of periciliary liquid and mucus from airway surfaces
6. Standard therapy for cystic fibrosis lung disease
7. New therapeutic strategies for CF lung disease
8. Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5′-nucleotide receptor in human airway epithelial cells
9. Uridine-5′-triphosphate (UTP) clearance from canine airway surfaces and metabolism in the systemic vasculature
10. Acute safety and effects on mucociliary clearance of aerosolized uridine 5-triphosphate +/- amiloride in normal adults
11. Effect of uridine 5-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis
12. 2 receptor agonist, stimulates mucociliary clearance and enhances sputum expectoration
13. 2 receptor agonist and ion channel modulator for the treatment of cystic fibrosis: Results from initial phase 1 study
14. The diagnosis of cystic fibrosis: A consensus statement
15. Mucociliary clearance in patients with cystic fibrosis and normal subjects
16. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis
17. 2+ and cAMP
18. Nucleotide regulation of goblet cells, in human airway epithelial explants: Normal exocytosis in cystic fibrosis
19. Human airway ion transport
20. Human airway ion transport
21. Effect of aerosolized uridine-5′-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia
22. Effects of INS 365, a P2Y2 receptor agonist, on components of the mucociliary clearance system